Author:
Rössler Annika,Riepler Lydia,Bante David,Laer Dorothee von,Kimpel Janine
Abstract
AbstractRecently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.529 (Omicron) has been described.Here, we analyze titers of neutralizing antibodies of sera from convalescent or vaccinated individuals against the new B.1.1.529 variant and compared them with titers against other Variants of Concern (B.1.1.7, B.1.351, B.1617.2) using replication competent SARS-CoV-2 variants.We found that sera from vaccinated individuals neutralized the B.1.1.529 variant to a much lesser extent than any other variant analyzed. Neutralization capacity against B.1.1.529 was maintained best against sera from super immune individuals (infected and vaccinated or vaccinated and infected).
Publisher
Cold Spring Harbor Laboratory
Reference4 articles.
1. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. 26.11.2021; Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.
2. Network for Genomic Surveillance in South Africa (NGS-SA). SARS-CoV-2 Sequencing Update 26 November 2021. Available from: https://www.nicd.ac.za/wp-content/uploads/2021/11/Update-of-SA-sequencing-data-from-GISAID-26-Nov_Final.pdf
3. Pulliamn JRC , van Schalkwyk C , Govender N et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. Dec 2, 2021. (https://doi.org/10.1101/2021.11.11.21266068) preprint.
4. Comparison of 4 SARS-CoV-2 neutralization assays;Vaccines (Basel),2020
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献